GINKGO BIOWORKS HOLDINGS
NYSE: DNA (Ginkgo Bioworks Holdings, Inc.)
Kemas kini terakhir: 11 jam lalu10.08
1.34 (15.33%)
| Penutupan Terdahulu | 8.74 |
| Buka | 8.46 |
| Jumlah Dagangan | 1,568,396 |
| Purata Dagangan (3B) | 1,192,359 |
| Modal Pasaran | 579,387,328 |
| Harga / Jualan (P/S) | 2.73 |
| Harga / Buku (P/B) | 0.780 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2024 |
| Margin Keuntungan | -298.78% |
| Margin Operasi (TTM) | -58.68% |
| EPS Cair (TTM) | -12.89 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 60.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 55.84% |
| Nisbah Semasa (MRQ) | 5.79 |
| Aliran Tunai Operasi (OCF TTM) | -334.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -317.24 M |
| Pulangan Atas Aset (ROA TTM) | -20.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -63.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Ginkgo Bioworks Holdings, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.70 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 6.15% |
| % Dimiliki oleh Institusi | 68.55% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Anchorage Capital Group, L.L.C. | 30 Sep 2024 | 1,746,363 |
| Opaleye Management Inc. | 30 Sep 2024 | 820,202 |
| Sb Investment Advisers (Uk) Ltd | 30 Sep 2024 | 610,729 |
| Meteora Capital, Llc | 30 Sep 2024 | 509,952 |
| Erste Asset Management Gmbh | 30 Sep 2024 | 500,000 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SLOAN HARRY | 10.70 | - | 235,780 | 2,522,846 |
| Jumlah Keseluruhan Kuantiti Bersih | 235,780 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 2,522,846 | |||
| Purata Pembelian Keseluruhan ($) | 10.70 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SLOAN HARRY | Pengarah | 11 Dec 2024 | Diperolehi (+) | 235,780 | 10.70 | 2,522,846 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Dec 2024 | Pengumuman | Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program |
| 12 Nov 2024 | Pengumuman | Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing |
| 12 Nov 2024 | Pengumuman | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results |
| 05 Nov 2024 | Pengumuman | Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation |
| 24 Sep 2024 | Pengumuman | NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |